For patients receiving salvage radiation therapy and 6 mo of androgen deprivation therapy for prostate cancer recurrence after radical prostatectomy, addition of abiraterone + apalutamide improved outcomes for patients with prostate-specific antigen >0.5 ng/ml.
European Urology published a clinical update in Research Highlights on 10 Feb 2026.
The item focuses on FORMULA-509: A Multicenter Randomized Trial of Postprostatectomy Salvage Radiotherapy and 6 months of a GNRH Agonist with Either Bicalutamide or Abiraterone Acetate plus Prednisone and Apalutamide.
Review the original article for the full source wording and details.